Julio Rosenstock, MD
Biography & Research Background
Julio Rosenstock, MD, is a clinical researcher affiliated with Velocity Clinical Research at Medical City (Dallas, TX, USA) and a world-renowned expert in diabetes clinical trials and incretin-based therapies. He led the Phase 2 clinical trial assessing the safety and efficacy of retatrutide in people with type 2 diabetes, published in The Lancet in 2023. His research highlighted the drug's ability to provide robust, dose-dependent reductions in both HbA1c (up to -2.02%) and body weight compared to placebo and the active comparator dulaglutide. Dr. Rosenstock has been a principal investigator on numerous landmark diabetes drug trials and has authored hundreds of peer-reviewed publications. His key publications include "Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA" (2023, The Lancet). Julio Rosenstock is being referenced as one of the leading scientists involved in retatrutide research. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure US Peptide and this doctor.
External Profiles
Authored Research Profiles (1)
Julio Rosenstock, MD is referenced as a leading researcher in the following peptide research profiles on Pure U.S. Peptides:
Julio Rosenstock, MD is being referenced as one of the leading scientists involved in the research and development of the peptides listed above. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of any product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure U.S. Peptides and this researcher. The purpose of citing the researcher is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying these peptides.